Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Therapy Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Advances in Precision Oncology: The Role of Targeted Therapies and Immunotherapy in Modern Cancer Care

Abstract

Recent advancements in cancer treatment have brought hope and progress to the challenging field of cancer care. This review examines five key areas of advancement: immunotherapy, targeted therapy, precision medicine, CAR T-cell therapy, and the integration of nanotechnology and liquid biopsies. Immunotherapy harnesses the immune system to combat cancer. This review also discusses examples of successful treatments and potential side effects. Targeted therapy focuses on specific abnormalities within cancer cells, demonstrating effectiveness in various cancers. Precision medicine customises therapy based on a person's genetic profile, demonstrating promising results and taking potential negative effects into account. CAR T-cell therapy and liquid biopsies represent exciting frontiers in cancer research and treatment. Advances in nanotechnology may further contribute to enhancing the precision and efficacy of these approaches. They offer targeted therapies, improved imaging, and non-invasive monitoring.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947356323250227063508
2025-03-12
2025-05-23

  • From This Site

    /content/journals/cctr/10.2174/0115733947356323250227063508
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Demaria O. Cornen S. Daëron M. Morel Y. Medzhitov R. Vivier E. Harnessing innate immunity in cancer therapy. Nature 2019 574 7776 45 56 10.1038/s41586‑019‑1593‑5 31578484
    [Google Scholar]
  2. Asher N. Ben-Betzalel G. Lev-Ari S. Shapira-Frommer R. Steinberg-Silman Y. Gochman N. Schachter J. Meirson T. Markel G. Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma. Cancers 2020 12 8 2329 10.3390/cancers12082329 32824780
    [Google Scholar]
  3. Edsjö A. Holmquist L. Geoerger B. Nowak F. Gomon G. Alix-Panabières C. Staaf J. Ploeger C. Lassen U. Le Tourneau C. Lehtiö J. Ott P.A. von Deimling A. Fröhling S. Voest E. Klauschen F. Dienstmann R. Alshibany A. Siu L.L. Stenzinger A. Precision cancer medicine: Concepts, current practice, and future developments. J. Intern. Med. 2023 294 4 455 481 10.1111/joim.13709 37641393
    [Google Scholar]
  4. Malone E.R. Oliva M. Sabatini P.J.B. Stockley T.L. Siu L.L. Molecular profiling for precision cancer therapies. Genome Med. 2020 12 1 8 10.1186/s13073‑019‑0703‑1 31937368
    [Google Scholar]
  5. Vijayakumar G. McCroskery S. Palese P. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. J. Virol. 2020 94 3 e01677-19 10.1128/JVI.01677‑19 31694938
    [Google Scholar]
  6. Schiffman J.D. Fisher P.G. Gibbs P. Early detection of cancer: Past, present, and future. Am. Soc. Clin. Oncol. Educ. Book 2015 ••• 35 57 65 10.14694/EdBook_AM.2015.35.57 25993143
    [Google Scholar]
  7. Are C. Murthy S.S. Sullivan R. Schissel M. Chowdhury S. Alatise O. Anaya D. Are M. Balch C. Bartlett D. Brennan M. Cairncross L. Clark M. Deo S.V.S. Dudeja V. D’Ugo D. Fadhil I. Giuliano A. Gopal S. Gutnik L. Ilbawi A. Jani P. Kingham T.P. Lorenzon L. Leiphrakpam P. Leon A. Martinez-Said H. McMasters K. Meltzer D.O. Mutebi M. Zafar S.N. Naik V. Newman L. Oliveira A.F. Park D.J. Pramesh C.S. Rao S. Subramanyeshwar Rao T. Bargallo-Rocha E. Romanoff A. Rositch A.F. Rubio I.T. Salvador de Castro Ribeiro H. Sbaity E. Senthil M. Smith L. Toi M. Turaga K. Yanala U. Yip C.H. Zaghloul A. Anderson B.O. Global cancer surgery: Pragmatic solutions to improve cancer surgery outcomes worldwide. Lancet Oncol. 2023 24 12 e472 e518 10.1016/S1470‑2045(23)00412‑6 37924819
    [Google Scholar]
  8. Perera S.K. Jacob S. Wilson B.E. Ferlay J. Bray F. Sullivan R. Barton M. Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: A population-based modelling study. Lancet Oncol. 2021 22 2 182 189 10.1016/S1470‑2045(20)30675‑6 33485458
    [Google Scholar]
  9. Chambers D.A. Feero W.G. Khoury M.J. Convergence of implementation science, precision medicine, and the learning health care system: A new model for biomedical research. JAMA 2016 315 18 1941 1942 10.1001/jama.2016.3867 27163980
    [Google Scholar]
  10. Fujigaki S. Nishiumi S. Kobayashi T. Suzuki M. Iemoto T. Kojima T. Ito Y. Daiko H. Kato K. Shouji H. Honda K. Azuma T. Yoshida M. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomarkers Med. 2018 12 8 827 840 10.2217/bmm‑2017‑0449 30043633
    [Google Scholar]
  11. Pernas S. Tolaney S.M. HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance. Ther. Adv. Med. Oncol. 2019 11 1758835919833519 10.1177/1758835919833519 30911337
    [Google Scholar]
  12. Baselga J. Cortés J. Kim S.B. Im S.A. Hegg R. Im Y.H. Roman L. Pedrini J.L. Pienkowski T. Knott A. Clark E. Benyunes M.C. Ross G. Swain S.M. CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012 366 2 109 119 10.1056/NEJMoa1113216 22149875
    [Google Scholar]
  13. González-Martín A. Pothuri B. Vergote I. DePont Christensen R. Graybill W. Mirza M.R. McCormick C. Lorusso D. Hoskins P. Freyer G. Baumann K. Jardon K. Redondo A. Moore R.G. Vulsteke C. O’Cearbhaill R.E. Lund B. Backes F. Barretina-Ginesta P. Haggerty A.F. Rubio-Pérez M.J. Shahin M.S. Mangili G. Bradley W.H. Bruchim I. Sun K. Malinowska I.A. Li Y. Gupta D. Monk B.J. PRIMA/ENGOT-OV26/GOG-3012 Investigators Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 2019 381 25 2391 2402 10.1056/NEJMoa1910962 31562799
    [Google Scholar]
  14. Reck M. Rodríguez-Abreu D. Robinson A.G. Hui R. Csőszi T. Fülöp A. Gottfried M. Peled N. Tafreshi A. Cuffe S. O’Brien M. Rao S. Hotta K. Leiby M.A. Lubiniecki G.M. Shentu Y. Rangwala R. Brahmer J.R. KEYNOTE-024 Investigators Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 2016 375 19 1823 1833 10.1056/NEJMoa1606774 27718847
    [Google Scholar]
  15. Redman J.M. Steinberg S.M. Gulley J.L. Quick efficacy seeking trial (QuEST1): A novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. J. Immunother. Cancer 2018 6 1 91 10.1186/s40425‑018‑0409‑8 30227893
    [Google Scholar]
  16. Bachelot T. Ciruelos E. Schneeweiss A. Puglisi F. Peretz-Yablonski T. Bondarenko I. Paluch-Shimon S. Wardley A. Merot J.L. du Toit Y. Easton V. Lindegger N. Miles D. Bouzid K. Campone M. Coudert B. Nowecki Z. Errihani H. Dalenc F. Ferreira A. Mano M. Ricci F. Kalofonos H. Andreetta C. Montemurro F. Barrett S. Zhang Q. Mavroudis D. Matus J. Beato C. Hu X. Gaafar R. Abdel Azeem H. Perrin C. Ettl J. Lang I. Verma S. Li H. Brain E. Hoffmann O. Cariello A. Tondini C. Altwegeiri T. Loman N. Lux M. Frassoldati A. Aziz Z. Salas F. Streb J. Wronski A. Menjón Beltrán S. Cicin I. Schmid P. Laing R. Tong Z. Boer K. Juhasz B. Gianni L. Curigliano G. Juarez A. Susnjar S. Matos E. Uslu R. Wildiers H. Cruz M. Bourgeois H. von Schumann R. Stemmer S. Vásquez F.M. Dominguez A. Wojtukiewicz M. Trifunovic J. Illarramendi J.J. Garcia L. Peron Y.I. Echarri M.J. Voitko N. Wheatley D. Waters S. De Boer R. Jerusalem G. Cocquyt V. Barrios C. Panasci L. Mattson J. Tanner M. Gozy M. Vasilopoulos G. Revesz J. Latini L. Gridelli C. Lazaro J. Gonzalez A. Barnadas Molins A. Martinez E. Alarcón J. Arance A. Klint L. Kovalyov O. Baird R. Yeo B. McCarthy N. Greil R. Wang S. Artignan X. Augereau P. Juhasz-Boess I. Ngan R. Goldberg H. Di Costanzo F. Ferraù F. Aleknavicius E. Rashid K. Costa L. Angel Garcia J. de la Cruz L.R. López López R. Del Val O. Ozyilkan O. Azribi F. Verrill M. Turner N. Beith J. Petzer A. Andrade J. Bernstein V. Rayson D. Saad Eldin I. Achille M. Mueller V. Gennari A. Cascinu S. Ghosn M. El-Saghir N. Van den Bosch J. Oosterkamp R. Kukulska M. Pelaez I. Hernandez C. del Mar Gordon M. Dalmau E. Alonso J.L. Aksoy S. Coskun H.S. Shparyk Y. Varughese M. Panwar U. Barraclough L. Levitt N. Hicks J. Rigg A. Allen M. Castillo C. Fein L.E. Stuart-Harris R. Singer C. Stoeger H. Smiljanic S. Feng J. Cedeño M. Berdah J.F. Orfeuvre H. Goncalves A. Grischke E-M. Simon E. Wagner S. Efremidou A. Papazisis K. Evron E. Inbar M. Baruch N.B. Geffen D. Karminsky N. Ruggeri E.M. Luigi C. Grasso D. Juozaityte E. Rafael Rodriguez Cid J. Roerdink H. Siddiqi N. Passos Coelho J.L. Garre E.G. Garcia A. Martínez Jañez N. Lopez Ceballos M.H. Mele M. García M. Arcediano A. McAdam K. Perren T. Hicks J. Taylor W. Humphreys A. Vera R. Kaen L.A. Steger G. Andel J. de Grève J. Huizing M. Hegg R. Joy A. Sehdev S. Kütner R. Ruohola J. Dohollou N. Grosjean J. Laplaige P. Largillier R. Martin P. Pottier V. Alexandre J. Christensen B. Zahm D-M. Khandan F. Lueck H-J. Fountzilas G. Fried G. Giacobino A. Bonetti A. Guerra Y.C. Van Warmerdam L. Van der Velden A. Vrijaldenhoven S. de Jongh F. Cavero M. Andres Conejero R. Murias A. Saura S. Oltra A. Redondo A. Ribelles N. Bachmeier K. Joffe J. Chakraborti P. Beresford M. Butt M. Poole C. Yordi G. Woodward N. Amorim G. Califaretti N. Fox S. Robidoux A. Li N.L. Li N. Jiang J. Soria T. Padrik P. Saarni O. Genet D. Catala S. Barletta H. Teixeira L. Facchini T. Hesse T. Kühn T. Ober A. Repp R. Schroeder W. Pectasides D. Bodoky G. Kahan Z. Jiveliouk I. Rosengarten O. Alabiso O. Perez M. Van de Wouw Y. Smok-Kalwat J. Damasceno M. Sousa G. Abulkhair O. Antón Torres A. Martinez M.P. Garcia Mata J. Jesús Florián Jerico M.S. Llombart A. Sanchez R. Torrego J.C. Garate C.O. Rodriguez C. Llorente R. de Prado D.S. Cortés J. Llorca C. Galán A. Viñas Villaro G. Narbe U. Bjömeklett H.G. Westwell S. Newby J. Jafri M. Rodríguez R. Alonso I. PERUSE investigators Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann. Oncol. 2019 30 5 766 773 10.1093/annonc/mdz061 30796821
    [Google Scholar]
  17. Wahida A. Buschhorn L. Fröhling S. Jost P.J. Schneeweiss A. Lichter P. Kurzrock R. The coming decade in precision oncology: Six riddles. Nat. Rev. Cancer 2023 23 1 43 54 10.1038/s41568‑022‑00529‑3 36434139
    [Google Scholar]
  18. Pupa S.M. Ligorio F. Cancila V. Franceschini A. Tripodo C. Vernieri C. Castagnoli L. HER2 signaling and breast cancer stem cells: The bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness. Cancers (Basel) 2021 13 19 4778 10.3390/cancers13194778 34638263
    [Google Scholar]
  19. Gandhi L. Rodríguez-Abreu D. Gadgeel S. Esteban E. Felip E. De Angelis F. Domine M. Clingan P. Hochmair M.J. Powell S.F. Cheng S.Y.S. Bischoff H.G. Peled N. Grossi F. Jennens R.R. Reck M. Hui R. Garon E.B. Boyer M. Rubio-Viqueira B. Novello S. Kurata T. Gray J.E. Vida J. Wei Z. Yang J. Raftopoulos H. Pietanza M.C. Garassino M.C. KEYNOTE-189 Investigators Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N. Engl. J. Med. 2018 378 22 2078 2092 10.1056/NEJMoa1801005 29658856
    [Google Scholar]
  20. Lee M. Lee H. Cheon G.J. Kim H.S. Chung H.H. Kim J.W. Park N.H. Song Y.S. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer. Eur. Radiol. 2017 27 1 16 23 10.1007/s00330‑016‑4368‑5 27121932
    [Google Scholar]
  21. Kelly P.N. The cancer immunotherapy revolution. Science 2018 359 6382 1344 1345 10.1126/science.359.6382.1344 29567702
    [Google Scholar]
  22. Westin J.R. Oluwole O.O. Kersten M.J. Miklos D.B. Perales M.A. Ghobadi A. Rapoport A.P. Sureda A. Jacobson C.A. Farooq U. van Meerten T. Ulrickson M. Elsawy M. Leslie L.A. Chaganti S. Dickinson M. Dorritie K. Reagan P.M. McGuirk J. Song K.W. Riedell P.A. Minnema M.C. Yang Y. Vardhanabhuti S. Filosto S. Cheng P. Shahani S.A. Schupp M. To C. Locke F.L. ZUMA-7 Investigators Kite Members Survival with Axicabtagene Ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 2023 389 2 148 157 10.1056/NEJMoa2301665 37272527
    [Google Scholar]
  23. Kalbasi A. Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 2020 20 1 25 39 10.1038/s41577‑019‑0218‑4 31570880
    [Google Scholar]
  24. Ibrahim J. De Schutter E. Op de Beeck K. GSDME: A potential ally in cancer detection and treatment. Trends Cancer 2021 7 5 392 394 10.1016/j.trecan.2020.12.002 33422423
    [Google Scholar]
  25. Sonnenschein C. Soto A.M. Over a century of cancer research: Inconvenient truths and promising leads. PLoS Biol. 2020 18 4 e3000670 10.1371/journal.pbio.3000670 32236102
    [Google Scholar]
  26. Havel J.J. Chowell D. Chan T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 2019 19 3 133 150 10.1038/s41568‑019‑0116‑x 30755690
    [Google Scholar]
  27. Peterson C. Denlinger N. Yang Y. Recent advances and challenges in cancer immunotherapy. Cancers 2022 14 16 3972 10.3390/cancers14163972 36010965
    [Google Scholar]
  28. Champiat S. Dercle L. Ammari S. Massard C. Hollebecque A. Postel-Vinay S. Chaput N. Eggermont A. Marabelle A. Soria J.C. Ferté C. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin. Cancer Res. 2017 23 8 1920 1928 10.1158/1078‑0432.CCR‑16‑1741 27827313
    [Google Scholar]
  29. Janopaul-Naylor J.R. Shen Y. Qian D.C. Buchwald Z.S. The abscopal effect: A review of pre-clinical and clinical advances. Int. J. Mol. Sci. 2021 22 20 11061 10.3390/ijms222011061 34681719
    [Google Scholar]
  30. Goldberg S.B. Gettinger S.N. Mahajan A. Chiang A.C. Herbst R.S. Sznol M. Tsiouris A.J. Cohen J. Vortmeyer A. Jilaveanu L. Yu J. Hegde U. Speaker S. Madura M. Ralabate A. Rivera A. Rowen E. Gerrish H. Yao X. Chiang V. Kluger H.M. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 17 7 976 983 10.1016/S1470‑2045(16)30053‑5 27267608
    [Google Scholar]
  31. Mansfield A.S. Herbst R.S. de Castro G. Jr Hui R. Peled N. Kim D.W. Novello S. Satouchi M. Wu Y.L. Garon E.B. Reck M. Robinson A.G. Samkari A. Piperdi B. Ebiana V. Lin J. Mok T.S.K. Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin. Res. Rep. 2021 2 8 100205 10.1016/j.jtocrr.2021.100205 34590048
    [Google Scholar]
  32. Mishra A.K. Ali A. Dutta S. Banday S. Malonia S.K. Emerging trends in immunotherapy for cancer. Diseases 2022 10 3 60 10.3390/diseases10030060 36135216
    [Google Scholar]
  33. Khamaneh A.J. Rahimi S. Abbas M.H. Rahimi S. Mehmandoust S. Rastgoo A. Heydarian A. Eskandari V. Trends in electrochemical biosensors for the early diagnosis of breast cancer through the detection of relevant biomarkers. Chemical. Physics. Impact. 2024 8 100425 10.1016/j.chphi.2023.100425
    [Google Scholar]
  34. Ribas A. Wolchok J.D. Cancer immunotherapy using checkpoint blockade. Science 2018 359 6382 1350 1355 10.1126/science.aar4060 29567705
    [Google Scholar]
  35. Larkin J. Chiarion-Sileni V. Gonzalez R. Grob J.J. Rutkowski P. Lao C.D. Cowey C.L. Schadendorf D. Wagstaff J. Dummer R. Ferrucci P.F. Smylie M. Hogg D. Hill A. Márquez-Rodas I. Haanen J. Guidoboni M. Maio M. Schöffski P. Carlino M.S. Lebbé C. McArthur G. Ascierto P.A. Daniels G.A. Long G.V. Bastholt L. Rizzo J.I. Balogh A. Moshyk A. Hodi F.S. Wolchok J.D. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 2019 381 16 1535 1546 10.1056/NEJMoa1910836 31562797
    [Google Scholar]
  36. Powles T. Csőszi T. Özgüroğlu M. Matsubara N. Géczi L. Cheng S.Y.S. Fradet Y. Oudard S. Vulsteke C. Morales Barrera R. Fléchon A. Gunduz S. Loriot Y. Rodriguez-Vida A. Mamtani R. Yu E.Y. Nam K. Imai K. Homet Moreno B. Alva A. Cascallar D.V. Varela M. Lazzaro M.F. Kaen D.L. Gatica G. Flores D.H. Falco A. Molina M. Van Aelst F. Vulsteke C. Sautois B. Machiels J-P. Schallier D. Brust L. Rapatoni L. Azevedo S.J. Marinho G. Soares J.P.H. Dzik C. Almeida Silva J. Fay A.P. Gingerich J. Fradet Y. Ferrario C. Potvin K. Vanhuyse M. Abdelsalam M. Cheng S. Caglevic C. Reyes F. Leal J.L. Francisco F. Ibanez C. Joly F. Laguerre B. Ladoire S. Flechon A. Topart D. Huillard O. Oudard S. Gross-Goupil M. Culine S. Loriot Y. Gravis G. Reichardt P. Retz M. Herden J. Pfister D. Ohlman C. Stoeckle M. Wirth M. Lorch A. Niegisch G. Goebell P.J. Boegemann M. Merseburger A. Gakis G. Bedke J. Neisius A. Thomas C. Hoefner T. Telekes A. Kosa J.E. Revesz J. Bodoky G. Csoszi T. Csejtei A. Geczi L. Ruzsa A. Kolonics Z. Erfan J. McDermott R. Bambury R. Sella A. Frank S.J. Kejzman D. Goldman O. Rosenbaum E. Peer A. Berger R. Rouvinov K. Sarid D. Fukasawa S. Arai G. Yamaguchi A. Yokomizo A. Takayama T. Kinoshita H. Kikuchi E. Mizuno R. Fujii Y. Sassa N. Matsukawa Y. Fujimoto K. Matsubara N. Tanikawa T. Tomita Y. Nishimura K. Tsujihata M. Oyama M. Masumori N. Kanayama H. Takano T. Miura Y. Miyazaki J. Joraku A. Kimura T. Yamamoto Y. Kobayashi K. De Wit R. Aarts M. Gerritsen W. Los M. Beerepoot L. Izmailov A. Gorelov S.I. Alekseev B.Y. Semenov A. Kostorov V.A. Alekseev S.M. Zyryanov A. Oschepkov V.N. Shidin V.A. Vladimirov V.I. Gafanov R.A. Karlov P.A. Anderson D.B. Shepherd L. Cohen G.L. Rapoport B.L. Ruff P. Lee N. Bae W.K. Lee H.J. Herranz U.A. Rodriguez-Vida A. Morales Barrera R. Grande E. Alonso Gordoa T. Guma Padro J. Gauna D.C. Arranz J.A. Munoz Langa J. Sarrio R.G. Montesa Pino A. Juan Fita M.J. Su Y-L. Lin Y-C. Su W-P. Shen Y-C. Chang Y-H. Huang Y-H. Sriuranpong V. Chansriwong P. Srimuninnimit V. Danchaivijitr P. Abali H. Yavuz S. Ozyilkan O. Sendur M.A.N. Ekenel M. Ozguroglu M. Arslan C. Gunduz S. Ozdogan M. Birtle A. Powles T. Huddart R. de Santis M. Zarkar A. Evans L. Hussain S. DiSimone C. Muina A.F. Schlegel P. Jhangiani H.S. Harrison M. Slater D.E. Wright D. Percent I.J. Lin J. Hwang C. Mamtani R. Gupta S. Bajaj M. Galamaga R. Eklund J. Wallace J. Shtivelband M. Suh J.J-G. Burhani N. Eadens M. Gunturu K. Burgess E. Wong J. Chaudhry A. Van Veldhuizen P. Graff S. Thomas C.A. Schnadig I.D. Carneiro B. Hussain M. Morgans A. Fitzharris J.T. Oliff I.A. Vuky J. Hauke R. Baron A. Joshi M. Bolemon B.H. Jiang P. Mega A.E. Markus M. Pfanzelter N. Lawler W.E. Cobb P.W. Courtright J.G. Jain S. Doshi G. Gunuganti V.K. Sartor O.A. Cole S.W. Babiker H. Uchio E.M. Drakaki A. Mannuel H.D. Alva A. Guancial E. Fung C. Charles A. Amato R.J. Arriaga Y. Bowman I. Ades S. Dreicer R. Yu E. Quinn D.I. Fleming M. KEYNOTE-361 Investigators Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomised, open-label, phase 3 trial. Lancet Oncol. 2021 22 7 931 945 10.1016/S1470‑2045(21)00152‑2 34051178
    [Google Scholar]
  37. Chen R. Gopal A.K. Smith S.E. Ansell S.M. Rosenblatt J.D. Savage K.J. Connors J.M. Engert A. Larsen E.K. Huebner D. Fong A. Younes A. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016 128 12 1562 1566 10.1182/blood‑2016‑02‑699850 27432875
    [Google Scholar]
  38. Harrington K.J. Ferris R.L. Gillison M. Tahara M. Argiris A. Fayette J. Schenker M. Bratland Å. Walker J.W.T. Grell P. Even C. Chung C.H. Redman R. Coutte A. Salas S. Grant C. de Azevedo S. Soulières D. Hansen A.R. Wei L. Khan T.A. Miller-Moslin K. Roberts M. Haddad R. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: The phase 2 CheckMate 714 randomized clinical trial. JAMA Oncol. 2023 9 6 779 789 10.1001/jamaoncol.2023.0147 37022706
    [Google Scholar]
  39. Motzer R.J. Tannir N.M. McDermott D.F. Arén Frontera O. Melichar B. Choueiri T.K. Plimack E.R. Barthélémy P. Porta C. George S. Powles T. Donskov F. Neiman V. Kollmannsberger C.K. Salman P. Gurney H. Hawkins R. Ravaud A. Grimm M.O. Bracarda S. Barrios C.H. Tomita Y. Castellano D. Rini B.I. Chen A.C. Mekan S. McHenry M.B. Wind-Rotolo M. Doan J. Sharma P. Hammers H.J. Escudier B. CheckMate 214 Investigators Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 2018 378 14 1277 1290 10.1056/NEJMoa1712126 29562145
    [Google Scholar]
  40. El-Khoueiry A.B. Sangro B. Yau T. Crocenzi T.S. Kudo M. Hsu C. Kim T.Y. Choo S.P. Trojan J. Welling T.H. III Meyer T. Kang Y.K. Yeo W. Chopra A. Anderson J. dela Cruz C. Lang L. Neely J. Tang H. Dastani H.B. Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017 389 10088 2492 2502 10.1016/S0140‑6736(17)31046‑2 28434648
    [Google Scholar]
  41. Kantarjian H. Stein A. Gökbuget N. Fielding A.K. Schuh A.C. Ribera J.M. Wei A. Dombret H. Foà R. Bassan R. Arslan Ö. Sanz M.A. Bergeron J. Demirkan F. Lech-Maranda E. Rambaldi A. Thomas X. Horst H.A. Brüggemann M. Klapper W. Wood B.L. Fleishman A. Nagorsen D. Holland C. Zimmerman Z. Topp M.S. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 2017 376 9 836 847 10.1056/NEJMoa1609783 28249141
    [Google Scholar]
  42. Bekoz H. Ozbalak M. Karadurmus N. Paydas S. Turker A. Toptas T. Tuglular T.F. Altuntas F. Cakar M.K. Sonmez M. Gulbas Z. Demir N. Kaynar L. Yildirim R. Karadogan I. Arat M. Kapucu I. Aslan N.A. Ozkocaman V. Turgut M. Yuksel M.K. Ozcan M. Hacioglu S.K. Barista I. Demirkaya M. Saydam G. Toprak S.K. Yilmaz M. Demirkol O. Ferhanoglu B. Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience. Ann. Hematol. 2020 99 11 2565 2576 10.1007/s00277‑020‑04077‑4 32507911
    [Google Scholar]
  43. Kaufman H.L. Russell J. Hamid O. Bhatia S. Terheyden P. D’Angelo S.P. Shih K.C. Lebbé C. Linette G.P. Milella M. Brownell I. Lewis K.D. Lorch J.H. Chin K. Mahnke L. von Heydebreck A. Cuillerot J.M. Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 17 10 1374 1385 10.1016/S1470‑2045(16)30364‑3 27592805
    [Google Scholar]
  44. Puzanov I. Diab A. Abdallah K. Bingham C.O. III Brogdon C. Dadu R. Hamad L. Kim S. Lacouture M.E. LeBoeuf N.R. Lenihan D. Onofrei C. Shannon V. Sharma R. Silk A.W. Skondra D. Suarez-Almazor M.E. Wang Y. Wiley K. Kaufman H.L. Ernstoff M.S. Society for Immunotherapy of Cancer Toxicity Management Working Group Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 2017 5 1 95 10.1186/s40425‑017‑0300‑z 29162153
    [Google Scholar]
  45. Postow M.A. Sidlow R. Hellmann M.D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 2018 378 2 158 168 10.1056/NEJMra1703481 29320654
    [Google Scholar]
  46. Boshuizen J. Peeper D.S. Rational cancer treatment combinations: An urgent clinical need. Mol. Cell 2020 78 6 1002 1018 10.1016/j.molcel.2020.05.031 32559422
    [Google Scholar]
  47. Jiang Z. Sun T. Wang X. Liu Q. Yan M. Tong Z. Geng C. Tang J. Yin Y. Yu G. Wang J. Su W. Wang S. Pan Y. Yang H. A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer. J. Clin. Oncol. 2022 40 16_suppl 1102 1102 10.1200/JCO.2022.40.16_suppl.1102
    [Google Scholar]
  48. Duffy M.J. Harbeck N. Nap M. Molina R. Nicolini A. Senkus E. Cardoso F. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur. J. Cancer 2017 75 284 298 10.1016/j.ejca.2017.01.017 28259011
    [Google Scholar]
  49. Vogel C.L. Cobleigh M.A. Tripathy D. Gutheil J.C. Harris L.N. Fehrenbacher L. Slamon D.J. Murphy M. Novotny W.F. Burchmore M. Shak S. Stewart S.J. Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2023 41 9 1638 1645 10.1200/JCO.22.02516 36921335
    [Google Scholar]
  50. Qu W. Fu C. Han W. Luo H. Quan J. Chen L. Liao Y. Hu C. Hu H. Niu Y. Xu D. Chen M. Chen J. Liu Y. Chen G. Luo Z. Shi B. Sun Y. Zhou F. Zhou A. A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma. Eur. J. Cancer 2024 205 114096 10.1016/j.ejca.2024.114096 38772302
    [Google Scholar]
  51. Swain S.M. Miles D. Kim S.B. Im Y.H. Im S.A. Semiglazov V. Ciruelos E. Schneeweiss A. Loi S. Monturus E. Clark E. Knott A. Restuccia E. Benyunes M.C. Cortés J. Agajanian R. Ahmad R. Aktas B. Alencar V.H. Amadori D. Andrade J. André Franke F. Angiolini C. Aogi K. Armor J. Arpornwirat W. Assersohn L. Audeh W. Aulitzky W. Azevedo S. Bartoli M.A. Batista Lopez N. Bianconi M. Biganzoli L. Birhiray R. Bitina M. Blachy R. Blackwell K. Blanchard R. Blanchet P. Boiangiu I. Bower B. Brezden-Masley C. Brufsky A. Budde L. Caguioa P. Calvo L. Campone M. Carroll R.R. Castro H. Chan V. Charu V. Cinieri S. Clemens M. Conejo E.A. Côrtes E. Coudert B. Cronemberger E. Cubero D. Dakhil S. Daniel B. Davidson N. De Fatima Gaui M. De La Cruz S. Del Pilar M. Delgado G. Ellerton J.A. Estuardo C. Fehrenbacher L. Ferrero J-M. Flynn P.J. Foszczynska-Kloda M. Franco S. Fujii H. Gallagher C. Gamucci T. Giacomi N. Gil I Gil M. Gonzalez Martin A. Gorbunova V. Gotovkin E. Green N. Grincuka E. Grischke E-M. Hansen V. Hargis J. Hauschild M. Hegg R. Hendricks C. Hermann R. Hoff P. Horiguchi J. Hornedo Muguiro J. Iacobelli S. Inoue K. Ismael G. Itoh Y. Iwata D.H. Jendiroba D. Jochim R. Jones A. Just M. Kallab A. Karwal M. Kashiwaba M. Kato G. Kaufman P.A. Kellokumpu-Lehtinen P. Kirsch A. Kiselev I. Klein P. Kohno N. Kopp M. Kostovska-Maneva L. Kotliar M. Kudaba I. Kümmel S. Kuroi K. Lacava J. Latini L. Lee S.C. Lichinitser M. Lobo C. Maintz C. Maneecahvakajorn J. Marmé A. Martinez G. Masuda N. Matwiejuk M. Merculov V. Michaelson R. Miguel L. Monroy H. Montemurro F. Morales S. Moura R. Mueller V. Mulatero C. Nakagami K. Nakayama T. Neidhart J. Nguyen A. Nishimura R. Ogata H. O’reilly S. O’rourke T. Otero Reye D. Ouyang X. Patel R. Patel T. Pedrini J.L. Pereira R. Perez A. Peterson C. Pienkowski T. Pinczowski H. Polikoff J. Polkowski W. Price P.E. Prill S. Priou F. Purkalne G. Pyrhoenen S. Quackenbush R. Rai Y. Ribelles N. Ro J. Robinson A. Robles R. Rodriguez G. Roman L. Saji S. Sanchez-Rovira P. Sato N. Schmidt M. Schumacher C. Senecal F. Sharma P. Shen Z. Shirinkin V. Simoncini E. Sirisinha T. Smith R. Sohn J-H. Soldic Z. Soria T. Spicer D. Srimuninnimit V. Sriuranpong V. Staroslawska E. Stefanovski P. Sunpaweravong P. Taguchi J. Takeda K. Tellez-Trevilla G. Thomas R. Thomssen C. Toache Z. Tokuda Y. Tomczak P. Tosello C. Tsugawa K. Tudtud D. Ueno T. Van Eyll B. Varela M. Vasev N. Vrbanec D. Wang X. Wang L. Watanabe J. Waterhouse D. Wesenberg B. Wheatley D. Wong Z.W. Yadav S. Yadav S. Yardley D. Yau T-K. Yeo W. Ying C. Youn Oh D. CLEOPATRA study group Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 21 4 519 530 10.1016/S1470‑2045(19)30863‑0 32171426
    [Google Scholar]
  52. Santoni-Rugiu E. Melchior L.C. Urbanska E.M. Jakobsen J.N. de Stricker K. Grauslund M. Sørensen J.B. Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Differences and similarities with acquired resistance. Cancers 2019 11 7 923 10.3390/cancers11070923 31266248
    [Google Scholar]
  53. Hecht J.R. Cohn A. Dakhil S. Saleh M. Piperdi B. Cline-Burkhardt M. Tian Y. Go W.Y. SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin. Colorectal Cancer 2015 14 2 72 80 10.1016/j.clcc.2014.12.009 25982297
    [Google Scholar]
  54. Menzer C. Menzies A.M. Carlino M.S. Reijers I. Groen E.J. Eigentler T. de Groot J.W.B. van der Veldt A.A.M. Johnson D.B. Meiss F. Schlaak M. Schilling B. Westgeest H.M. Gutzmer R. Pföhler C. Meier F. Zimmer L. Suijkerbuijk K.P.M. Haalck T. Thoms K.M. Herbschleb K. Leichsenring J. Menzer A. Kopp-Schneider A. Long G.V. Kefford R. Enk A. Blank C.U. Hassel J.C. Targeted therapy in advanced melanoma with rare BRAF mutations. J. Clin. Oncol. 2019 37 33 3142 3151 10.1200/JCO.19.00489 31580757
    [Google Scholar]
  55. Sacha T. Imatinib in chronic myeloid leukemia: An overview. Mediterr. J. Hematol. Infect. Dis. 2013 6 1 e2014007 10.4084/mjhid.2014.007 24455116
    [Google Scholar]
  56. McLaughlin P. Grillo-López A.J. Link B.K. Levy R. Czuczman M.S. Williams M.E. Heyman M.R. Bence-Bruckler I. White C.A. Cabanillas F. Jain V. Ho A.D. Lister J. Wey K. Shen D. Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 2023 41 2 154 162 10.1200/JCO.22.02403 36603541
    [Google Scholar]
  57. Davis I.D. Martin A.J. Stockler M.R. Begbie S. Chi K.N. Chowdhury S. Coskinas X. Frydenberg M. Hague W.E. Horvath L.G. Joshua A.M. Lawrence N.J. Marx G. McCaffrey J. McDermott R. McJannett M. North S.A. Parnis F. Parulekar W. Pook D.W. Reaume M.N. Sandhu S.K. Tan A. Tan T.H. Thomson A. Tu E. Vera-Badillo F. Williams S.G. Yip S. Zhang A.Y. Zielinski R.R. Sweeney C.J. ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 2019 381 2 121 131 10.1056/NEJMoa1903835 31157964
    [Google Scholar]
  58. Ferguson F.M. Gray N.S. Kinase inhibitors: The road ahead. Nat. Rev. Drug Discov. 2018 17 5 353 377 10.1038/nrd.2018.21 29545548
    [Google Scholar]
  59. Mok T.S. Wu Y.L. Ahn M.J. Garassino M.C. Kim H.R. Ramalingam S.S. Shepherd F.A. He Y. Akamatsu H. Theelen W.S.M.E. Lee C.K. Sebastian M. Templeton A. Mann H. Marotti M. Ghiorghiu S. Papadimitrakopoulou V.A. AURA3 Investigators Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N. Engl. J. Med. 2017 376 7 629 640 10.1056/NEJMoa1612674 27959700
    [Google Scholar]
  60. Fornasier G. Francescon S. Baldo P. An update of efficacy and safety of cetuximab in metastatic colorectal cancer: A narrative review. Adv. Ther. 2018 35 10 1497 1509 10.1007/s12325‑018‑0791‑0 30218345
    [Google Scholar]
  61. Wolchok J.D. Chiarion-Sileni V. Gonzalez R. Grob J.J. Rutkowski P. Lao C.D. Cowey C.L. Schadendorf D. Wagstaff J. Dummer R. Ferrucci P.F. Smylie M. Butler M.O. Hill A. Márquez-Rodas I. Haanen J.B.A.G. Guidoboni M. Maio M. Schöffski P. Carlino M.S. Lebbé C. McArthur G. Ascierto P.A. Daniels G.A. Long G.V. Bas T. Ritchings C. Larkin J. Hodi F.S. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 2022 40 2 127 137 10.1200/JCO.21.02229 34818112
    [Google Scholar]
  62. Naqvi K. Jabbour E. Skinner J. Anderson K. Dellasala S. Yilmaz M. Ferrajoli A. Bose P. Thompson P. Alvarado Y. Jain N. Takahashi K. Burger J. Estrov Z. Borthakur G. Pemmaraju N. Paul S. Cortes J. Kantarjian H.M. Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer 2020 126 1 67 75 10.1002/cncr.32504 31553487
    [Google Scholar]
  63. DeVita V.T. Jr Rosenberg S.A. Two hundred years of cancer research. N. Engl. J. Med. 2012 366 23 2207 2214 10.1056/NEJMra1204479 22646510
    [Google Scholar]
  64. Turtle C.J. Hanafi L.A. Berger C. Gooley T.A. Cherian S. Hudecek M. Sommermeyer D. Melville K. Pender B. Budiarto T.M. Robinson E. Steevens N.N. Chaney C. Soma L. Chen X. Yeung C. Wood B. Li D. Cao J. Heimfeld S. Jensen M.C. Riddell S.R. Maloney D.G. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 2016 126 6 2123 2138 10.1172/JCI85309 27111235
    [Google Scholar]
  65. Neelapu S.S. Tummala S. Kebriaei P. Wierda W. Gutierrez C. Locke F.L. Komanduri K.V. Lin Y. Jain N. Daver N. Westin J. Gulbis A.M. Loghin M.E. de Groot J.F. Adkins S. Davis S.E. Rezvani K. Hwu P. Shpall E.J. Chimeric antigen receptor T-cell therapy: Assessment and management of toxicities. Nat. Rev. Clin. Oncol. 2018 15 1 47 62 10.1038/nrclinonc.2017.148 28925994
    [Google Scholar]
  66. Maude S.L. Laetsch T.W. Buechner J. Rives S. Boyer M. Bittencourt H. Bader P. Verneris M.R. Stefanski H.E. Myers G.D. Qayed M. De Moerloose B. Hiramatsu H. Schlis K. Davis K.L. Martin P.L. Nemecek E.R. Yanik G.A. Peters C. Baruchel A. Boissel N. Mechinaud F. Balduzzi A. Krueger J. June C.H. Levine B.L. Wood P. Taran T. Leung M. Mueller K.T. Zhang Y. Sen K. Lebwohl D. Pulsipher M.A. Grupp S.A. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 2018 378 5 439 448 10.1056/NEJMoa1709866 29385370
    [Google Scholar]
  67. Turtle C.J. Hanafi L.A. Berger C. Hudecek M. Pender B. Robinson E. Hawkins R. Chaney C. Cherian S. Chen X. Soma L. Wood B. Li D. Heimfeld S. Riddell S.R. Maloney D.G. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells. Sci. Transl. Med. 2016 8 355 355ra116 10.1126/scitranslmed.aaf8621 27605551
    [Google Scholar]
  68. Shah N.N. Fry T.J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 2019 16 6 372 385 10.1038/s41571‑019‑0184‑6 30837712
    [Google Scholar]
  69. Hay K.A. Hanafi L.A. Li D. Gust J. Liles W.C. Wurfel M.M. López J.A. Chen J. Chung D. Harju-Baker S. Cherian S. Chen X. Riddell S.R. Maloney D.G. Turtle C.J. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood 2017 130 21 2295 2306 10.1182/blood‑2017‑06‑793141 28924019
    [Google Scholar]
  70. Dezfuli A.A.Z. Abu-Elghait M. Salem S.S. Recent insights into nanotechnology in colorectal cancer. Appl. Biochem. Biotechnol. 2024 196 7 4457 4471 10.1007/s12010‑023‑04696‑3 37751009
    [Google Scholar]
  71. Kensler T.W. Spira A. Garber J.E. Szabo E. Lee J.J. Dong Z. Dannenberg A.J. Hait W.N. Blackburn E. Davidson N.E. Foti M. Lippman S.M. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev. Res. (Phila.) 2016 9 1 2 10 10.1158/1940‑6207.CAPR‑15‑0406 26744449
    [Google Scholar]
  72. Le Tourneau C. Kamal M. Bièche I. Precision medicine in oncology: What is it exactly and where are we? Per. Med. 2018 15 5 351 353 10.2217/pme‑2018‑0036 30260312
    [Google Scholar]
  73. Advani R.H. Skrypets T. Civallero M. Spinner M.A. Manni M. Kim W.S. Shustov A.R. Horwitz S.M. Hitz F. Cabrera M.E. Dlouhy I. Vassallo J. Pileri S.A. Inghirami G. Montoto S. Vitolo U. Radford J. Vose J.M. Federico M. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: Final report from the international T-cell Project. Blood 2021 138 3 213 220 10.1182/blood.2020010387 34292324
    [Google Scholar]
  74. Wat J. Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J. Allergy Clin. Immunol. Pract. 2022 10 2 460 466 10.1016/j.jaip.2021.10.037 34757064
    [Google Scholar]
  75. Robinson A. Idecabtagene Vicleucel (Abecma®). Oncol. Times 2021 43 10 21 10.1097/01.COT.0000753336.18581.7d
    [Google Scholar]
  76. Voeller J. Sondel P.M. Advances in anti-GD2 immunotherapy for the treatment of high-risk neuroblastoma. J. Pediatr. Hematol. Oncol. 2019 41 3 163 169 10.1097/MPH.0000000000001369 30897608
    [Google Scholar]
  77. Zhao H. Wang Y. Bao L. Chen C. Engineering nano–bio interfaces from nanomaterials to nanomedicines. Acc. Mater. Res. 2022 3 8 812 829 10.1021/accountsmr.2c00072
    [Google Scholar]
  78. Yang J. Wang X. Wang B. Park K. Wooley K. Zhang S. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. Adv. Drug Deliv. Rev. 2022 190 114525 10.1016/j.addr.2022.114525 36100142
    [Google Scholar]
  79. Mosleh-Shirazi S. Abbasi M. Moaddeli M. Vaez A. Shafiee M. Kasaee S.R. Amani A.M. Hatam S. Nanotechnology advances in the detection and treatment of cancer: An overview. Nanotheranostics 2022 6 4 400 423 10.7150/ntno.74613 36051855
    [Google Scholar]
  80. Milan J. Niemczyk K. Kus-Liśkiewicz M. Treasure on the earth—gold nanoparticles and their biomedical applications. Materials 2022 15 9 3355 10.3390/ma15093355 35591689
    [Google Scholar]
  81. Cotin G. Piant S. Mertz D. Felder-Flesch D. Begin-Colin S. Iron oxide nanoparticles for biomedical applications: Synthesis, functionalization, and application. Iron Oxide Nanoparticles for Biomedical Applications Elsevier 2018 43 88 10.1016/B978‑0‑08‑101925‑2.00002‑4
    [Google Scholar]
  82. Harshita Barkat M.A. Beg S. Pottoo F.H. Ahmad F.J. Nanopaclitaxel therapy: An evidence based review on the battle for next-generation formulation challenges. Nanomedicine (Lond.) 2019 14 10 1323 1341 10.2217/nnm‑2018‑0313 31124758
    [Google Scholar]
  83. Habibi N. Quevedo D.F. Gregory J.V. Lahann J. Emerging methods in therapeutics using multifunctional nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2020 12 4 e1625 10.1002/wnan.1625 32196991
    [Google Scholar]
  84. von Roemeling C. Jiang W. Chan C.K. Weissman I.L. Kim B.Y.S. Breaking down the barriers to precision cancer nanomedicine. Trends Biotechnol. 2017 35 2 159 171 10.1016/j.tibtech.2016.07.006 27492049
    [Google Scholar]
  85. Park H.S. Kang B. Chon H.J. Im H.S. Lee C.K. Kim I. Kang M.J. Hwang J.E. Bae W.K. Cheon J. Park J.O. Hong J.Y. Kang J.H. Kim J.H. Lim S.H. Kim J.W. Kim J.W. Yoo C. Choi H.J. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: A multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open 2021 6 2 100049 10.1016/j.esmoop.2021.100049 33578192
    [Google Scholar]
  86. Adrianzen Herrera D. Ashai N. Perez-Soler R. Cheng H. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: An evaluation of the clinical evidence. Expert Opin. Pharmacother. 2019 20 1 95 102 10.1080/14656566.2018.1546290 30439289
    [Google Scholar]
  87. Omuro A. Brandes A.A. Carpentier A.F. Idbaih A. Reardon D.A. Cloughesy T. Sumrall A. Baehring J. van den Bent M. Bähr O. Lombardi G. Mulholland P. Tabatabai G. Lassen U. Sepulveda J.M. Khasraw M. Vauleon E. Muragaki Y. Di Giacomo A.M. Butowski N. Roth P. Qian X. Fu A.Z. Liu Y. Potter V. Chalamandaris A.G. Tatsuoka K. Lim M. Weller M. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-oncol. 2023 25 1 123 134 10.1093/neuonc/noac099 35419607
    [Google Scholar]
  88. de Gramont A. Figer A. Seymour M. Homerin M. Hmissi A. Cassidy J. Boni C. Cortes-Funes H. Cervantes A. Freyer G. Papamichael D. Le Bail N. Louvet C. Hendler D. de Braud F. Wilson C. Morvan F. Bonetti A. Leucovorin and Fluorouracil with or without Oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2023 41 33 5080 5089 10.1200/JCO.22.02773 37967516
    [Google Scholar]
  89. Pantel K. Alix-Panabières C. Liquid biopsy and minimal residual disease: Latest advances and implications for cure. Nat. Rev. Clin. Oncol. 2019 16 7 409 424 10.1038/s41571‑019‑0187‑3 30796368
    [Google Scholar]
  90. Gorgannezhad L. Umer M. Islam M.N. Nguyen N.T. Shiddiky M.J.A. Circulating tumor DNA and liquid biopsy: Opportunities, challenges, and recent advances in detection technologies. Lab Chip 2018 18 8 1174 1196 10.1039/C8LC00100F 29569666
    [Google Scholar]
  91. Siravegna G. Marsoni S. Siena S. Bardelli A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 2017 14 9 531 548 10.1038/nrclinonc.2017.14 28252003
    [Google Scholar]
  92. Lokeshwar S.D. Klaassen Z. Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat. Rev. Urol. 2021 18 7 433 442 10.1038/s41585‑021‑00470‑4 34002069
    [Google Scholar]
  93. Fu B. Yan P. Zhang S. Lu Y. Pan L. Tang W. Chen S. Chen S. Zhang A. Liu W. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis. Markers 2018 2018 1 11 10.1155/2018/6437104 29849824
    [Google Scholar]
  94. Abbosh C. Birkbak N.J. Wilson G.A. Jamal-Hanjani M. Constantin T. Salari R. Le Quesne J. Moore D.A. Veeriah S. Rosenthal R. Marafioti T. Kirkizlar E. Watkins T.B.K. McGranahan N. Ward S. Martinson L. Riley J. Fraioli F. Al Bakir M. Grönroos E. Zambrana F. Endozo R. Bi W.L. Fennessy F.M. Sponer N. Johnson D. Laycock J. Shafi S. Czyzewska-Khan J. Rowan A. Chambers T. Matthews N. Turajlic S. Hiley C. Lee S.M. Forster M.D. Ahmad T. Falzon M. Borg E. Lawrence D. Hayward M. Kolvekar S. Panagiotopoulos N. Janes S.M. Thakrar R. Ahmed A. Blackhall F. Summers Y. Hafez D. Naik A. Ganguly A. Kareht S. Shah R. Joseph L. Quinn A.M. Crosbie P.A. Naidu B. Middleton G. Langman G. Trotter S. Nicolson M. Remmen H. Kerr K. Chetty M. Gomersall L. Fennell D.A. Nakas A. Rathinam S. Anand G. Khan S. Russell P. Ezhil V. Ismail B. Irvin-Sellers M. Prakash V. Lester J.F. Kornaszewska M. Attanoos R. Adams H. Davies H. Oukrif D. Akarca A.U. Hartley J.A. Lowe H.L. Lock S. Iles N. Bell H. Ngai Y. Elgar G. Szallasi Z. Schwarz R.F. Herrero J. Stewart A. Quezada S.A. Peggs K.S. Van Loo P. Dive C. Lin C.J. Rabinowitz M. Aerts H.J.W.L. Hackshaw A. Shaw J.A. Zimmermann B.G. Swanton C. Erratum: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2018 554 7691 264 10.1038/nature25161 29258292
    [Google Scholar]
  95. Ribas A. Daud A. Pavlick A.C. Gonzalez R. Lewis K.D. Hamid O. Gajewski T.F. Puzanov I. Wongchenko M. Rooney I. Hsu J.J. Yan Y. Park E. McArthur G.A. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin. Cancer Res. 2020 26 1 46 53 10.1158/1078‑0432.CCR‑18‑4180 31732523
    [Google Scholar]
  96. Zhang Y. Yao Y. Xu Y. Li L. Gong Y. Zhang K. Zhang M. Guan Y. Chang L. Xia X. Li L. Jia S. Zeng Q. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat. Commun. 2021 12 1 11 10.1038/s41467‑020‑20162‑8 33397889
    [Google Scholar]
  97. Abbosh C. Frankell A.M. Harrison T. Kisistok J. Garnett A. Johnson L. Veeriah S. Moreau M. Chesh A. Chaunzwa T.L. Weiss J. Schroeder M.R. Ward S. Grigoriadis K. Shahpurwalla A. Litchfield K. Puttick C. Biswas D. Karasaki T. Black J.R.M. Martínez-Ruiz C. Bakir M.A. Pich O. Watkins T.B.K. Lim E.L. Huebner A. Moore D.A. Godin-Heymann N. L’Hernault A. Bye H. Odell A. Roberts P. Gomes F. Patel A.J. Manzano E. Hiley C.T. Carey N. Riley J. Cook D.E. Hodgson D. Stetson D. Barrett J.C. Kortlever R.M. Evan G.I. Hackshaw A. Daber R.D. Shaw J.A. Aerts H.J.W.L. Licon A. Stahl J. Jamal-Hanjani M. Lester J.F. Bajaj A. Nakas A. Sodha-Ramdeen A. Ang K. Tufail M. Chowdhry M.F. Scotland M. Boyles R. Rathinam S. Wilson C. Marrone D. Dulloo S. Fennell D.A. Matharu G. Primrose L. Boleti E. Cheyne H. Khalil M. Richardson S. Cruickshank T. Price G. Kerr K.M. Benafif S. Gilbert K. Naidu B. Osman A. Lacson C. Langman G. Shackleford H. Djearaman M. Kadiri S. Middleton G. Leek A. Hodgkinson J.D. Totten N. Montero A. Smith E. Fontaine E. Granato F. Doran H. Novasio J. Rammohan K. Joseph L. Bishop P. Shah R. Moss S. Joshi V. Crosbie P. Brown K. Carter M. Chaturvedi A. Priest L. Oliveira P. Lindsay C.R. Blackhall F.H. Krebs M.G. Summers Y. Clipson A. Tugwood J. Kerr A. Rothwell D.G. Kilgour E. Dive C. Schwarz R.F. Kaufmann T.L. Wilson G.A. Rosenthal R. Van Loo P. Szallasi Z. Sokac M. Salgado R. Diossy M. Demeulemeester J. Bunkum A. Stewart A. Magness A. Rowan A. Karamani A. Toncheva A. Chain B. Campbell B.B. Castignani C. Bailey C. Weeden C.E. Lee C. Richard C. Naceur-Lombardelli C. Pearce D.R. Karagianni D. Levi D. Hoxha E. Larose Cadieux E. Colliver E. Nye E. Grönroos E. Gálvez-Cancino F. Athanasopoulou F. Gimeno-Valiente F. Kassiotis G. Stavrou G. Mastrokalos G. Zhai H. Lowe H.L. Matos I. Goldman J. Reading J.L. Herrero J. Rane J.K. Nicod J. Lam J.M. Hartley J.A. Peggs K.S. Enfield K.S.S. Selvaraju K. Thol K. Ng K.W. Chen K. Dijkstra K. Thakkar K. Ensell L. Shah M. Vasquez M. Litovchenko M. Werner Sunderland M. Hill M.S. Dietzen M. Leung M. Escudero M. Angelova M. Tanić M. Sivakumar M. Kanu N. Chervova O. Lucas O. Al-Sawaf O. Prymas P. Hobson P. Pawlik P. Stone R.K. Bentham R. Hynds R.E. Vendramin R. Saghafinia S. López S. Gamble S. Ung S.K.A. Quezada S.A. Vanloo S. Zaccaria S. Hessey S. Boeing S. Beck S. Bola S.K. Denner T. Marafioti T. Mourikis T.P. Spanswick V. Barbè V. Lu W-T. Hill W. Liu W.K. Wu Y. Naito Y. Ramsden Z. Veiga C. Royle G. Collins-Fekete C-A. Fraioli F. Ashford P. Clark T. Forster M.D. Lee S.M. Borg E. Falzon M. Papadatos-Pastos D. Wilson J. Ahmad T. Procter A.J. Ahmed A. Taylor M.N. Nair A. Lawrence D. Patrini D. Navani N. Thakrar R.M. Janes S.M. Martinoni Hoogenboom E. Monk F. Holding J.W. Choudhary J. Bhakhri K. Scarci M. Hayward M. Panagiotopoulos N. Gorman P. Khiroya R. Stephens R.C.M. Wong Y.N.S. Bandula S. Sharp A. Smith S. Gower N. Dhanda H.K. Chan K. Pilotti C. Leslie R. Grapa A. Zhang H. AbdulJabbar K. Pan X. Yuan Y. Chuter D. MacKenzie M. Chee S. Alzetani A. Cave J. Scarlett L. Richards J. Ingram P. Austin S. Lim E. De Sousa P. Jordan S. Rice A. Raubenheimer H. Bhayani H. Ambrose L. Devaraj A. Chavan H. Begum S. Buderi S.I. Kaniu D. Malima M. Booth S. Nicholson A.G. Fernandes N. Shah P. Proli C. Hewish M. Danson S. Shackcloth M.J. Robinson L. Russell P. Blyth K.G. Dick C. Le Quesne J. Kirk A. Asif M. Bilancia R. Kostoulas N. Thomas M. Birkbak N.J. McGranahan N. Swanton C. TRACERx Consortium Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023 616 7957 553 562 10.1038/s41586‑023‑05776‑4 37055640
    [Google Scholar]
  98. Biohaven Pharmaceutical Holding Company Ltd Compositions and methods for treating cancer. Available from: https://worldwide.espacenet.com/patent/search/family/075912834/publication/WO2021097294A1?q=Compositions%20AND%20methods%20for%20treating%20cancer%20Surface%20Oncology%2C%20Inc.%20May%2020%2C%202021%20International%20Composition%2C%20Method
  99. Broad inst Inc Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway. WO Patent 2019094983A1 2018
  100. Cancer therapy. Available from: https://worldwide.espacenet.com/patent/search/family/059088211/citation/US2021283232A1?q=Methods%20AND%20compositions%20for%20treating%20cancer%20with%20PD-1%20pathway%20antagonists%20Janssen%20Biotech%2C%20Inc.%20September%209%2C%202021%20USA%20Method%2C%20Composition
  101. Focused interferon immunotherapy for the treatment of cancer CA Patent 2988619A1 2016
  102. Sharp m. Dohme c. Small molecule inhibitors of Kras g12c mutant. WO Patent 2021086833A1 2016
  103. Bristol Myers Squibb Co Treatment of pd-l1-negative melanoma using anti-pd-1 antibody and anti-la-4 antibody. 2021 Available from: https://worldwide.espacenet.com/patent/search/family/056087499/citation/JP2021105000A?q=Methods%20AND%20compositions%20for%20treating%20cancer%20Bristol-Myers%20Squibb%20Company%20April%2029%2C%202021%20International%20Method%2C%20Composition
  104. Novartis Ag. Uses of anti-Tgfβ antibodies and other therapeutic agents for the treatment of proliferative diseases. US Patent 20230056470A1 2016
  105. Bristol-Myers Squibb Company Compositions and methods of treating cancer. https://worldwide.espacenet.com/patent/search/family/065902748/citation/US11351163B2?q=US11351163B2
  106. Janssen Biotech Inc Methods for treating prostate cancer. WO Patent 2022060878A1 2021
  107. JANSSEN BIOTECH INC Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer. US Patent 20210093719A1 2016
  108. Janssen Biotech Inc Methods of treating prostate cancer with an anti- psma/cd3 antibody. WO Patent 2020212947A1 2020
  109. Noahm Inc Anticancer compositions comprising immune checkpoint inhibitors. WO Patent 2020141828A2 2018
  110. Noahm Inc Anticancer composition comprising metabolic anticancer drug. WO Patent 2021230600A1, 2021
  111. Abbvie Inc Protein tyrosine phosphatase inhibitors and methods of use thereof. CN Patent 112955438A, 2021
  112. Abbvie Inc Crystalline forms of an apoptosis-inducing agent. WO Patent 2021207581A1 2021
  113. Pharma Res Ltd Compositions comprising parabacteroides bacterial strains for treating cancer. WO Patent 2020120717A1 2019
  114. Omeros Corp Methods and compositions for treating cancer. US Patent 20100204312A1 2008
  115. Incyte Corporation Imidazolyl pyrimidinylamine compounds as Cdk2 inhibitors. WO Patent 2021030537A1 2020
  116. Incyte Corp Pyrido [3,2-D ] pyrimidine compounds as immunomodulators. CN Patent 115175734B 2020
  117. Heterocyclic compounds as immunomodulators Available from: Https://Worldwide.Espacenet.Com/Patent/Search/Family/058191548/citation/Us2021363137a1?Q=Compositions%20and%20methods%20for%20treating%20cancer%20incyte%20corporation%20may%2011%2c%202021%20composition%2c%20method
  118. Incyte Corp Imidazopyridazine compounds with activity as Alk2 inhibitors. CA Patent 115175734B 2021
  119. Incyte Corp Benzothiazole compounds and uses thereof. US Patent 10899755B2 2021
  120. Incyte Corp Carboxamide compounds and uses there of. US Patent 10800761B2 2019
  121. Univ Freiburg Albert Ludwigs Method for monitoring the response to neoadjuvant therapy for breast cancer. Available from: Https://Worldwide.Espacenet.Com/Patent/Search/Family/078617210/citation/Ep4180812a1?Q=Cancer
  122. Therapeutic composition for cancer treatment. https://Worldwide.Espacenet.Com/Patent/Search/Family/078676407/citation/Ep4180049a1?Q=Cancer
  123. Urteste SA Fret enzymatic substrate and uses thereof in liver cancer. CA Patent 3235007A1 2021
  124. Broad Inst Inc and Dana Farber Cancer Inst Inc Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes. WO Patent 2021247534A2 2021
  125. Dana Farber Cancer Inst Inc and Lee Patrick C. Methods for Modulating Mhc-I Expression and Immunotherapy Uses Thereof Methods for modulating mhc-i expression and immunotherapy uses thereof. WO Patent 2021247540A1 2021
  126. Broad Inst Inc Therapeutic targeting of malignant cells using tumor markers. Available from: https://Worldwide.Espacenet.Com/Patent/Search/Family/078412271/citation/Us2021347847a1?Q=Compositions%20and%20methods%20for%20targeted%20drug%20delivery%20using%20liposomes%20the%20brigham%20and%20women%27s%20hospital%2c%20inc.%20may%2011%2c%202021%20composition%2c%20method
  127. Genentech Inc Methods for treatment of cancer with an anti-tigit antagonist antibody. WO Patent 2021154761A1 2023
  128. Brigham & Women Hospital Inc Methods for drug screening and compositions useful for the inhibition of cell proliferation and/or cell survival. Available from:https://Worldwide.Espacenet.Com/Patent/Search/Family/076222469/citation/Wo2021113170a1?Q=Compositions%20and%20methods%20for%20targeted%20drug%20delivery%20using%20liposomes%20the%20brigham%20and%20women%27s%20hospital%2c%20inc.%20may%2011%2c%202021%20composition%2c%20method
  129. Broad Inst Inc, Massachusetts Inst Technology and Brigham & Womens Hospital Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis US Patent 11793787B2 2020
  130. Children’s Medical Center and Brigham & Women Hospital Inc Target synergistic cancer immunotherapy. Available from: https://Worldwide.Espacenet.Com/Patent/Search/Family/072667471/citation/Au2020253403a1?Q=Compositions%20and%20methods%20for%20targeted%20drug%20delivery%20using%20liposomes%20the%20brigham%20and%20women%27s%20hospital%2c%20inc.%20may%2011%2c%202021%20composition%2c%20method
  131. Mayo found medical education & res Herpesviral combination therapy for targeting cancer cells and cancer-associated stromal cells. 2023 Available from: https://worldwide.espacenet.com/patent/search/family/086242093/citation/WO2023081348A1?q=cancer
  132. Mayo found medical education & res Compositions and methods for detecting oral neoplasm. US Patent 20160018398A1 2010
  133. Memorial Sloan Kettering Cancer Center IL-33 antagonists and uses thereof. US Patent10774128B2 2014
  134. Memorial Sloan Kettering Cancer Center Memorial Hospital for Cancer and Allied Diseases Sloan Kettering inst Cancer Res. Combination inhibitors for treating fibrosis. Available from: https://worldwide.espacenet.com/patent/search/family/086242201/citation/WO2023081775A1?q=cancer
  135. Inst Nat Sante Rech Med, Univ Montpellier, Inst Regional Cancer Montpellier and Centre Hospitalier Univ De Nimes Methods and compositions for treating triple negative breast cancer. EP Patent 4427044A1 2022
  136. Ariel Scient Innovations Ltd Compositions and methods for cancer treatment. Available from:https://worldwide.espacenet.com/patent/search/family/086240740/citation/WO2023079556A1?q=cancer
  137. Strata Oncology Inc Cancer biomarkers for immune checkpoint inhibitors. AU Patent 2022381055A1 2022
  138. Zeno man Inc. Pi3k inhibitors and methods of treating cancer. 2023 Available from: https://worldwide.espacenet.com/patent/search/family/086241883/citation/WO2023081209A1?q=cancer
  139. Genentech Inc Methods and compositions for classifying and treating kidney cancer. 2023 Available from:https://worldwide.espacenet.com/patent/search/family/078821648/citation/WO2023080900A1?q=cancer
  140. Kernal Biologics Inc Oncoselective cancer therapy. Available from:https://worldwide.espacenet.com/patent/search/family/086242057/citation/WO2023081885A1?q=cancer
  141. A method for detecting cancer in a patient 2013 Available from:https://worldwide.espacenet.com/patent/search/family/084367259/citation/WO2023079183A1?q=cancer
  142. Memorial Sloan Kettering Cancer Center Methods and compositions for predicting cancer survival and Car T cell toxicity. US Patent 20240293481A1 2022
  143. Fred Hutchinson Cancer Center Treatments for cancers utilizing cell-targeted therapies and associated research protocols. CA Patent 3235607A1 2022
  144. Univ Chicago Methods and compositions for PKC-delta inhibition and cancer immunotherapy. WO Patent 2023081934A1 2022
  145. Primo Biotechnology Co Ltd Methods of noninvasive detection and specific treatment for cancer metastasis Available from:https://worldwide.espacenet.com/patent/search/family/086229115/citation/US202314Examples
  146. Cellestia Biotech Pharmaceutical combinations for the treatment of cancer. US Patent 9833431B2 2014
  147. Artiva Biotherapeutics Inc Affimed Gmbh and Gc Cell Corp Treatment of cancer with nk cells and multispecific engagers. Available from: https://worldwide.espacenet.com/patent/search/family/086242049/citation/WO2023081317A2?q=cancer
  148. Methods and materials for treating cancer. 2023 Available from: https://worldwide.espacenet.com/patent/search/family/086242204/citation/WO2023081803A2?q=cancer
/content/journals/cctr/10.2174/0115733947356323250227063508
Loading
Advances in Precision Oncology: The Role of Targeted Therapies and Immunotherapy in Modern Cancer Care
Bentham Science Publishers ; https://doi.org/10.2174/0115733947356323250227063508
/content/journals/cctr/10.2174/0115733947356323250227063508
/content/journals/cctr/10.2174/0115733947356323250227063508
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: precision ; immunotherapy ; nanotechnology ; cancer ; Advancements ; targeted therapy ; biopsies

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test